The debate for generics: a view on statin therapy

Source: JAMA Internal Medicine Area: News Related to the results of a survey of US Physicians in which researchers sought to determine how frequently physicians comply with requests for brand-name drugs or the factors predicting this behaviour, JAMA Internal Medicine has featured a review of the case for generics when considering statin therapy.   The review considers the following: . Comparing statin efficacy . The choice of generic statins   The authors conclude that "lowering LDL-C level does not always reduce cardiovascular risk, although risk reduction is the appropriate goal of therapy. Generic statins reduce patients' cardiovascular risk at a much lower cost than brand name statins. However, while previously, the highest doses of branded statins could claim some, albeit limited, benefit relative to generics, the availability of generic atorvastatin has simplified statin choice. There are now generic statins available that cover the full range of potencies and metabolic pathways ...
Source: NeLM - Cardiovascular Medicine - Category: Cardiology Source Type: news